Taro pharmaceutical industries ltd (TARO)
Income statement / Quarterly
Mar'12Mar'11
Sales, net

145,141

107,727

Cost of sales

45,971

44,617

Gross profit

99,170

63,110

Operating expenses:
Research and development

9,847

7,258

Selling, marketing, general and administrative

23,101

22,460

Settlements and loss contingencies

0

-

Total operating expenses

32,948

29,718

Operating income

66,222

33,392

Financial expenses (income), net

-1,000

-1,187

Other gain, net

-94

251

Income before income taxes

65,128

32,456

Tax expense

17,791

6,368

Income from continuing operations

47,337

26,088

Net loss from discontinued operations attributable to Taro

66

-135

Net income

47,403

25,953

Net (loss) income attributable to non-controlling interest

151

295

Net income attributable to Taro

47,252

25,658

Net income from continuing operations attributable to Taro

47,186

25,793

Net loss from discontinued operations attributable to Taro

66

-135

Net income attributable to Taro

47,252

25,658

Basic

1.06

0.58

Diluted

1.06

0.58

Basic

0.00

0.00

Diluted

0.00

0.00

Net income per ordinary share attributable to Taro:
Basic

1.06

0.58

Diluted

1.06

0.58

Weighted-average number of ordinary shares used to compute net income per share:
Basic

44,476

44,285

Diluted

44,589

44,447